Fig. 1.

CEA-directed CMI responses in treated patients. CMI (IFN-γ secretion) was assessed at baseline (pre) and after administrations of Ad5 [E1-, E2b-]-CEA(6D) (post). The highest CMI responses (regardless of time point) observed in the patients after treatment revealed a dose response. The highest CMI levels occurred in patients that received the highest dose of 5 × 10¹¹ VP (Cohort 5). The CMI responses for cohort 3/phase II and cohort 5 were significantly elevated (Mann–Whitney test) as compared to their baseline (pre) values. Specificity of the responses was demonstrated by the lack of reactivity with the irrelevant antigens β-galactosidase and HIV-gag (data not shown). For positive controls, PBMCs were exposed to concanavalin A (data not shown). Horizontal line and error bar indicate the mean ± SEM for each cohort